JPWO2023238929A1 - - Google Patents
Info
- Publication number
- JPWO2023238929A1 JPWO2023238929A1 JP2024527029A JP2024527029A JPWO2023238929A1 JP WO2023238929 A1 JPWO2023238929 A1 JP WO2023238929A1 JP 2024527029 A JP2024527029 A JP 2024527029A JP 2024527029 A JP2024527029 A JP 2024527029A JP WO2023238929 A1 JPWO2023238929 A1 JP WO2023238929A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022094420 | 2022-06-10 | ||
| PCT/JP2023/021535 WO2023238929A1 (ja) | 2022-06-10 | 2023-06-09 | ピミテスピブを含有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023238929A1 true JPWO2023238929A1 (https=) | 2023-12-14 |
| JPWO2023238929A5 JPWO2023238929A5 (https=) | 2026-02-20 |
Family
ID=89118411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527029A Pending JPWO2023238929A1 (https=) | 2022-06-10 | 2023-06-09 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250312280A1 (https=) |
| EP (1) | EP4537824A1 (https=) |
| JP (1) | JPWO2023238929A1 (https=) |
| KR (1) | KR20250022143A (https=) |
| CN (1) | CN119365195A (https=) |
| AU (1) | AU2023282693A1 (https=) |
| CA (1) | CA3258968A1 (https=) |
| MX (1) | MX2024015327A (https=) |
| TW (1) | TW202404585A (https=) |
| WO (1) | WO2023238929A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4608087B2 (ja) * | 1999-12-22 | 2011-01-05 | 富山化学工業株式会社 | 固形製剤の製造法 |
| PT2452940E (pt) | 2009-07-10 | 2015-02-27 | Taiho Pharmaceutical Co Ltd | Composto azabiciclo e seu sal |
| EP2498759B1 (en) * | 2009-11-13 | 2018-08-01 | AstraZeneca AB | Immediate release tablet formulations |
| MX353289B (es) * | 2011-05-25 | 2018-01-05 | Taiho Pharmaceutical Co Ltd | Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico. |
| RU2657783C2 (ru) | 2013-09-30 | 2018-06-15 | Тайхо Фармасьютикал Ко., Лтд. | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания |
| JP6537601B2 (ja) | 2015-05-12 | 2019-07-03 | 大鵬薬品工業株式会社 | アザ二環式化合物の結晶 |
| DK3646869T3 (da) | 2017-06-30 | 2025-09-15 | Taiho Pharmaceutical Co Ltd | Kemoterapi mod kræft under anvendelse af azabicycloforbindelse |
| BR112020005100A2 (pt) | 2017-09-15 | 2020-09-15 | Taiho Pharmaceutical Co., Ltd. | usos de um composto inibidor de hsp90 para produzir um agente profilático e/ou terapêutico para doenças que envolvem expressão de ido e para produzir uma composição farmacêutica para tratar tumores ido-positivos |
| JP6918204B2 (ja) * | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| AU2018423606B2 (en) | 2018-05-14 | 2024-10-10 | Taiho Pharmaceutical Co., Ltd. | Method of treating malignant tumor by azabicyclic compound |
-
2023
- 2023-06-09 KR KR1020257000541A patent/KR20250022143A/ko active Pending
- 2023-06-09 US US18/873,090 patent/US20250312280A1/en active Pending
- 2023-06-09 CA CA3258968A patent/CA3258968A1/en active Pending
- 2023-06-09 EP EP23819909.5A patent/EP4537824A1/en active Pending
- 2023-06-09 JP JP2024527029A patent/JPWO2023238929A1/ja active Pending
- 2023-06-09 WO PCT/JP2023/021535 patent/WO2023238929A1/ja not_active Ceased
- 2023-06-09 AU AU2023282693A patent/AU2023282693A1/en active Pending
- 2023-06-09 TW TW112121639A patent/TW202404585A/zh unknown
- 2023-06-09 CN CN202380046118.5A patent/CN119365195A/zh active Pending
-
2024
- 2024-12-10 MX MX2024015327A patent/MX2024015327A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3258968A1 (en) | 2025-04-18 |
| EP4537824A1 (en) | 2025-04-16 |
| TW202404585A (zh) | 2024-02-01 |
| CN119365195A (zh) | 2025-01-24 |
| KR20250022143A (ko) | 2025-02-14 |
| WO2023238929A1 (ja) | 2023-12-14 |
| US20250312280A1 (en) | 2025-10-09 |
| MX2024015327A (es) | 2025-02-10 |
| AU2023282693A1 (en) | 2025-01-02 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |